Info

New thrombosis

0.29 (0.17-0.50)

<0.001

0.32 (0.18-0.55)

<0.001

aDeath due to thrombosis, amputation secondary to HIT-associated thrombosis, or new thrombosis within a 37-day study period.

Abbreviations: ARG, argatroban; HIT, heparin-induced thrombocytopenia.

aDeath due to thrombosis, amputation secondary to HIT-associated thrombosis, or new thrombosis within a 37-day study period.

Abbreviations: ARG, argatroban; HIT, heparin-induced thrombocytopenia.

p < 0.001) and HITTS (hazard ratio, 0.39; 95% CI, 0.25 to 0.62; p < 0.001) (Table 3). The antithrombotic benefits remained significant after adjusting for patient age, gender, race, weight, and baseline platelet count. In each HIT presentation, the positive antithrombotic effect was driven by significant risk reductions in new thrombosis and death due to thrombosis (Table 3). The risk of amputation secondary to HIT-associated thrombosis was not different between groups.

0 0

Post a comment